PMID: 11901097Mar 20, 2002Paper

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

Drug Metabolism and Disposition : the Biological Fate of Chemicals
James E PatrickMitchell N Cayen

Abstract

Ezetimibe [SCH 58235; 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone], a selective cholesterol absorption inhibitor, is being developed for the treatment of primary hypercholesterolemia. The absorption, metabolism, and excretion of ezetimibe were characterized in eight healthy male volunteers in this single-center, single-dose, open-label study. Subjects received a single oral 20-mg dose of [14C]ezetimibe (approximately 100 microCi) with 200 ml of noncarbonated water after a 10-h fast. Concentrations of radioactivity and/or ezetimibe (conjugated and unconjugated) were determined in plasma, urine, and fecal samples. Ezetimibe was rapidly absorbed and extensively conjugated following oral administration. The main circulating metabolite in plasma was SCH 60663 [1-O-[4-[trans-(2S,3R)-1-(4-fluorophenyl)-4-oxo-3-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-2-azetidinyl]phenyl]-beta-D-glucuronic acid], the glucuronide conjugate of ezetimibe. Plasma concentration-time profiles of unconjugated and conjugated drug exhibited multiple peaks, indicating enterohepatic recycling. Approximately 78 and 11% of the administered [14C]ezetimibe dose were excreted in feces and urine, respectively, by ...Continue Reading

References

Jun 1, 1996·The American Journal of Medicine·J J Marcelino, K R Feingold
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
May 9, 2000·Clinical Pharmacology and Therapeutics·J FeelyA Kelly

❮ Previous
Next ❯

Citations

Sep 25, 2010·European Journal of Clinical Pharmacology·Jung-Woo BaeSeok-Yong Lee
Aug 7, 2002·Current Atherosclerosis Reports·Margaret E Brousseau, Ernst J Schaefer
Dec 10, 2003·Current Atherosclerosis Reports·Christie M Ballantyne
Oct 16, 2004·Current Cardiology Reports·Shailendra B Patel
Nov 8, 2003·Clinical Therapeutics·LilyAnn Jeu, Judy W M Cheng
Dec 31, 2002·Journal of the American College of Cardiology·Frank M Sacks
Aug 23, 2008·American Journal of Physiology. Gastrointestinal and Liver Physiology·Eric D LabontéPhilip N Howles
Jun 16, 2007·The Journal of Clinical Investigation·Ryan E TemelLiqing Yu
Aug 7, 2002·Clinical Pharmacokinetics·Michael S RobertsMichael Weiss
Oct 25, 2002·Drugs·Thomas Sudhop, Klaus von Bergmann
Mar 1, 2008·Indian Journal of Pharmaceutical Sciences·P C SharmaB Suresh
Mar 1, 2008·Indian Journal of Pharmaceutical Sciences·Metreyi SharmaS R Dhaneshwar
Mar 24, 2015·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Eman G NoumanHayam M Lotfy
Oct 17, 2006·Expert Opinion on Investigational Drugs·John R Burnett, Murray W Huff
Oct 31, 2003·Expert Opinion on Investigational Drugs·Pedro Iglesias, Juan J Díez
Dec 9, 2009·Expert Opinion on Drug Safety·Fabrizio MontecuccoFrançois Mach
Jan 14, 2010·Journal of Drug Targeting·Vikas BaliJaved Ali
Aug 9, 2005·Current Medical Research and Opinion·Larisa ReydermanPaul Statkevich
Sep 24, 2004·Current Medical Research and Opinion·Larisa ReydermanPaul Statkevich
Aug 25, 2004·Current Medical Research and Opinion·Teddy KosoglouDavid L Cutler
Aug 25, 2004·Current Medical Research and Opinion·Teddy KosoglouEnrico P Veltri
Jan 28, 2005·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M S KimS H Vincent
Feb 24, 2012·Pharmacological Reports : PR·Dariusz SuchyBogusław Okopień
Oct 18, 2011·The Journal of the Association of Nurses in AIDS Care : JANAC·Hazel Jones-Parker
Sep 16, 2006·Diabetes & Metabolism·T MeasP J Guillausseau
Nov 19, 2003·Pharmacotherapy·Edith A Nutescu, Nancy L Shapiro
Feb 24, 2006·Journal of Clinical Pharmacology·Arthur J BergmanJohn F Paolini
Jun 26, 2007·Journal of Atherosclerosis and Thrombosis·Harry R Davis, Enrico P Veltri
Dec 4, 2012·The Science of the Total Environment·Christian G Daughton, Ilene Sue Ruhoy
Mar 15, 2011·Atherosclerosis·Harry R DavisDavid R Neff
Dec 17, 2014·Frontiers in Pharmacology·Omar Patiño-RodríguezJosé Pérez-Urizar
May 29, 2015·Biotechnology, Biotechnological Equipment·Irfan PervaizWajahat Mahmood
Jul 21, 2005·The Annals of Pharmacotherapy·Sheri L KoshmanGlen J Pearson
May 30, 2003·The Annals of Pharmacotherapy·Vincent F Mauro, Chad E Tuckerman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.